Dr. Jill C. Beck
Claim this profileChildren's Hospital and Medical Center of Omaha
About Jill C. Beck
Education:
- Obtained MD (Doctor of Medicine) from the University of Nebraska Medical Center in 1997.
- Completed Residency in Pediatrics at the University of Nebraska Medical Center, Children's Hospital & Medical Center in 2000.
- Concluded Fellowship in Pediatric Hematology/Oncology at the University of Nebraska Medical Center, Children's Hospital & Medical Center in 2003.
Experience:
- Currently serves as a pediatric hematologist/oncologist at Children's Hospital and Medical Center of Omaha.
Area of expertise
Cancer
Jill C. Beck has run 18 trials for Cancer. Some of their research focus areas include:
Brain Tumor
Jill C. Beck has run 15 trials for Brain Tumor. Some of their research focus areas include:
Affiliated Hospitals
Children's Hospital And Medical Center Of Omaha
University Of Nebraska Medical Center
Clinical Trials Jill C. Beck is currently running
Selumetinib vs. Chemotherapy
for Brain Cancer
This trial is comparing a new drug, selumetinib, with standard chemotherapy to treat patients with a specific type of brain tumor. The patients do not have a certain genetic mutation and are not affected by a genetic disorder. Selumetinib works by blocking enzymes needed for tumor growth, while the standard drugs kill or stop tumor cells from dividing.
Recruiting
2 awards
Phase 3
Inotuzumab Ozogamicin
for Acute Lymphoblastic Leukemia
This phase III trial studies whether inotuzumab ozogamicin added to post-induction chemotherapy and immunotherapy (chemo-immunotherapy) for patients with High-Risk B-cell Acute Lymphoblastic Leukemia (B-ALL) improves outcomes. Inotuzumab ozogamicin is a monoclonal antibody, which is a type of protein that can bind to certain targets on the surface of cells. Inotuzumab ozogamicin is a monoclonal antibody that is linked to a type of chemotherapy called calicheamicin. Inotuzumab attaches to cancer cells by binding to the CD22 protein on the surface of the cancer cell and delivering calicheamicin inside the cells to kill them. Other drugs used in the chemotherapy regimen, such as cyclophosphamide, cytarabine, dexamethasone, doxorubicin, daunorubicin, methotrexate, leucovorin, mercaptopurine, prednisone, thioguanine, vincristine, and pegaspargase or calaspargase pegol work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Blinatumomab is a specialized type of monoclonal antibody known as a bispecific T-cell engager (BiTE). It works by simultaneously binding to CD19 on cancer cells and CD3 on normal immune cells, bringing them together to destroy leukemia cells. Blinatumomab is a standard part of chemo-immunotherapy treatment for B-ALL. This trial also studies the outcomes of patients with mixed phenotype acute leukemia (MPAL), and B-lymphoblastic lymphoma (B-LLy) when treated with ALL therapy without inotuzumab ozogamicin or blinatumomab. The overall goal of this study is to understand if adding inotuzumab ozogamicin to standard of care chemo-immunotherapy maintains or improves outcomes in High Risk B-cell Acute Lymphoblastic Leukemia (HR B-ALL). The first part of the study includes the first phase of therapy: Induction. This part will collect information on the leukemia, as well as the effects of the initial treatment, to classify patients into post-induction treatment groups. On the second part of this study, patients with HR B-ALL will receive the remainder of the chemotherapy cycles (consolidation, blinatumomab block 1, interim maintenance 1, blinatumomab block 2, delayed intensification, interim maintenance 2, maintenance), with some patients randomized to receive inotuzumab. The patients that receive inotuzumab will not receive part of consolidation or part of delayed intensification. Other aims of this study include evaluating 1) side effects of treatment using patient-reported outcomes and health-related quality of life, 2) the best ways to help patients adhere to oral chemotherapy regimens, 3) the relationship between levels of inotuzumab ozogamicin in the blood and side effects, 4) the impact of chemo-immunotherapy on the immune system and risk of infection, and 5) the impact of social determinants of health on outcomes. Finally, this study will be the first to track the outcomes of subjects with disseminated B-cell Lymphoblastic Leukemia (B-LLy) or Mixed Phenotype Acute Leukemia (MPAL) when treated with B-ALL chemotherapy.
Recruiting
2 awards
Phase 3
More about Jill C. Beck
Clinical Trial Related
6 years of experience running clinical trials · Led 54 trials as a Principal Investigator · 22 Active Clinical Trials
Treatments Jill C. Beck has experience with
- Cyclophosphamide
- Radiation Therapy
- Etoposide
- Doxorubicin Hydrochloride
- Cisplatin
- Methotrexate
Breakdown of trials Jill C. Beck has run
Cancer
Brain Tumor
Neuroblastoma
Brain Cancer
Langerhans Cell Histiocytosis
Other Doctors you might be interested in
Frequently asked questions
Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the ‘trial drug’ — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
What does Jill C. Beck specialize in?
Jill C. Beck focuses on Cancer and Brain Tumor. In particular, much of their work with Cancer has involved Stage I patients, or patients who are Stage IV.
Is Jill C. Beck currently recruiting for clinical trials?
Yes, Jill C. Beck is currently recruiting for 22 clinical trials in Omaha Nebraska. If you're interested in participating, you should apply.
Are there any treatments that Jill C. Beck has studied deeply?
Yes, Jill C. Beck has studied treatments such as Cyclophosphamide, Radiation Therapy, Etoposide.
What is the best way to schedule an appointment with Jill C. Beck?
Apply for one of the trials that Jill C. Beck is conducting.
What is the office address of Jill C. Beck?
The office of Jill C. Beck is located at: Children's Hospital and Medical Center of Omaha, Omaha, Nebraska 68114 United States. This is the address for their practice at the Children's Hospital and Medical Center of Omaha.
Is there any support for travel costs?
The coverage of travel expenses can vary greatly between different clinical trials. Please see more financial detail in the trials you’re interested to apply.
Unbiased Results
We believe in providing patients with all the options.
Your Data Stays Your Data
We only share your information with the clinical trials you're trying to access.
Verified Trials Only
All of our trials are run by licensed doctors, researchers, and healthcare companies.